MFG
CPRX icon

Mendota Financial Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Mendota Financial Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12
Closed -$239 – 550
2024
Q3 		$239 Buy
+12
New +$222 ﹤0.01% 565

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Mendota Financial Group's CPRX Position: Q4 2024 in Review

Mendota Financial Group sold out of Catalyst Pharmaceutical (CPRX) in Q4 2024, closing a stake of 12 shares — an estimated $239 sold.

Mendota Financial Group first reported a position in CPRX in Q3 2024 and held it in 1 quarter. The position peaked at $239 in Q3 2024. 336 funds tracked by Wall St. Rank hold CPRX as of Q4 2024.

  • Mendota Financial Group reported no remaining Catalyst Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • Mendota Financial Group sold 12 Catalyst Pharmaceutical shares in Q4 2024, an estimated $239.
  • Mendota Financial Group first reported a position in Catalyst Pharmaceutical in Q3 2024 and held it in 1 quarter.
  • Mendota Financial Group's Catalyst Pharmaceutical position peaked at $239 in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2024.

Based on Mendota Financial Group's 13F filing for Q4 2024, filed 14 Jan 2025.